Clinical Trials Logo

Hemangioendothelioma clinical trials

View clinical trials related to Hemangioendothelioma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06452160 Recruiting - Solid Tumor Clinical Trials

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

NCT ID: NCT06408441 Recruiting - Sarcoma,Soft Tissue Clinical Trials

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

EHE
Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic and predictive factors are lacking and many questions are still open on the optimal management. In the context of EURACAN, a prospective registry specifically dedicated to EHE was developed and launched with the aim of providing, through high-quality prospective data collection, a better understanding of this disease. The study design is a registry-based cohort study including only new cases of patients with a pathological and molecularly confirmed diagnosis of EHE. The objectives are to improve the understanding of EHE natural history, validate and identify new prognostic and predictive factors, clarify the activity and efficacy of currently available treatment options, describe treatment pattern. It is an hospital-based registry established in centres with expertise in EHE including adult patients with a new pathological and molecularly confirmed diagnosis of EHE starting from the 1st December 2023. The characteristics of each patient in the facility who meets the above-mentioned inclusion criteria will be collected prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. The data analyses will include descriptive statistics and analytical analyses. Multivariable Cox's proportional hazards model and Hazard ratios (HR) for all-cause or cause-specific mortality will be used to determine independent predictors of overall survival, recurrence and progression. The registry has been joined by 21 sarcoma reference centers across EU and UK, covering 10 countries. Patients' recruitment started in December 2023. The estimated completion date is December 2033 upon agreement on the achievement of all the registry objectives. The already established collaboration and participation of EHE patient's associations involved in the project will help in promoting the registry and fostering accrual. This registry has been developed with the support of EHE Rare Cancer Charity UK, STATER (Grant Agreement number: 947604, HP-PJ-2019) and EURACAN 2022 (Grant Agreement number: 101085486, EU4H-2022-ERN-IBA) European Health and Digital Executive Agency (HaDEA)

NCT ID: NCT05351216 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma

Start date: March 1, 2021
Phase:
Study type: Observational

To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration. To explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with KHE. To search for back-up plans for vaccination regimens for KHE patients taking sirolimus in children who do not respond to primary vaccination.

NCT ID: NCT05324384 Recruiting - Clinical trials for Hemangioendothelioma

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

Start date: April 5, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of different doses of sirolimus in the maintenance treatment of kaposiform hemangioendothelioma.

NCT ID: NCT05170282 Recruiting - Hepatoblastoma Clinical Trials

Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants

Start date: January 1, 2021
Phase:
Study type: Observational

Hepatic tumors in the perinatal period are associated with significant morbidity and mortality in affected patients. The conventional diagnostic tool, such as alpha-fetoprotein (AFP) shows limited value in diagnosis of infantile hepatic tumors. This retrospective-prospective study is aimed to evaluate the diagnostic efficiency of the deep learning system through analysis of magnetic resonance imaging (MRI) images before initial treatment.

NCT ID: NCT04921722 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

Start date: October 22, 2021
Phase: Phase 4
Study type: Interventional

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

NCT ID: NCT04056962 Recruiting - Clinical trials for Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma

Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

NCT ID: NCT04008238 Recruiting - Synovial Sarcoma Clinical Trials

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

PIPER
Start date: January 6, 2020
Phase: N/A
Study type: Interventional

This is a biology driven, monocentric study, designed to identify biomarkers of activity of trabectedin in patients with advanced non-L soft-tissue sarcoma. The aim of this study is to implement high-throughput profiling technologies to identify predictive biomarkers of trabectedin efficacy through sequential tumor biopsies and blood sample collection in sarcoma patients.

NCT ID: NCT03967834 Recruiting - Soft Tissue Sarcoma Clinical Trials

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

MIRAS
Start date: April 26, 2021
Phase: N/A
Study type: Interventional

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

NCT ID: NCT03001180 Recruiting - Vascular Anomaly Clinical Trials

Identification of Biomarkers for Patients With Vascular Anomalies

Start date: April 2015
Phase:
Study type: Observational

The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study. The study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank maintained by the Department of Hematology/Oncology.